3 news items
Novocure Reports First Quarter 2024 Financial Results
NVCR
2 May 24
benefit
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
NVCR
ZLAB
27 Mar 24
prospects and plans for developing and commercializing TTFields, the potential benefits of TTFields, and the potential treatment for patients with brain
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
NVCR
27 Mar 24
of life and stable cognition. This is a major benefit and is potentially practice changing."
Preliminary
- Prev
- 1
- Next